News Center

位置：

Honors Announcement

Group News

Media Reports

Shisi Pharmaceutical Group Honored as One of China’s Top 20 Most Competitive Listed Pharmaceutical Companies

Category:

Honors Announcement

发布时间：2020-11-30

【概要描述】 The China Pharmaceutical Innovation Gala was grandly held at the Hangzhou International Expo Center, where the organizers unveiled the Top 20 Chinese Listed Pharmaceutical Companies by Competitiveness, the Top 10 Chinese Listed Pharmaceutical Companies by Investment Value, and the Top 100 Innovative Chinese Pharmaceutical Enterprises. Shisi Pharmaceutical Group was named among the Top 20 Chinese Listed Pharmaceutical Companies by Competitiveness, marking its second inclusion on this prestigious list since 2019.

Shisi Pharmaceutical Group Honored as One of China’s Top 20 Most Competitive Listed Pharmaceutical Companies

On the evening of November 28, along the banks of West Lake, as the city lights began to twinkle and the scenery unfolded in all its splendor, the highly anticipated 2020 China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference (CHSESI), commonly known as the “Qisi Conference,” held its China Pharmaceutical Innovation Night Awards Ceremony at the Hangzhou International Expo Center. During the event, the conference unveiled the Top 20 Most Competitive Chinese Pharmaceutical Listed Companies, the Top 10 Most Investment-Attractive Chinese Pharmaceutical Listed Companies, and the Top 100 Innovative Chinese Pharmaceutical Enterprises. Shisi Pharmaceutical Group was honored as one of the Top 20 Most Competitive Chinese Pharmaceutical Listed Companies, marking its second consecutive inclusion on this prestigious list since 2019.

The China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference is co-hosted by the China Association of Pharmaceutical Enterprise Management, the China Society of Pharmaceutical Biotechnology, and the General Office of the Central Committee of the China Association for Promoting Democracy. As the pharmaceutical industry’s premier, most influential, and largest-scale event in China, the conference has been held annually since 2009. Upholding its mission to empower innovation and upgrading within the Chinese pharmaceutical sector, it brings together entrepreneurs, scientists, and investors to integrate key innovation drivers—including government policy, corporate leadership, technological advancement, capital investment, and clinical expertise—thereby establishing China’s most authoritative platform for launching innovative new pharmaceutical products and fostering value-driven connections across the industry ecosystem. The conference has garnered extensive attention from both the domestic pharmaceutical industry and the investment community, cultivating a strong brand reputation.

The China Top 20 Pharmaceutical Listed Companies Competitiveness Ranking has been held consecutively for 12 sessions to date and has earned widespread recognition within the industry. The ranking is conducted by a panel of industry experts who assess and score the competitiveness of major pharmaceutical companies listed on domestic and overseas stock exchanges for at least one year, registered in China or with their principal business operations based in China, boasting annual revenues exceeding RMB 100 million, and maintaining a solid credit record—evaluating them across five dimensions: entrepreneurship, capital, industry, resources, and management. In 2019, Shisi Pharmaceutical Group was included for the first time in the China Top 20 Pharmaceutical Listed Companies Competitiveness Ranking.

Shisi Pharmaceutical Group’s outstanding performance in the large-volume parenteral solutions market—characterized by meticulous operations and robust R&D innovation—has garnered widespread attention from both the product and capital markets. As a National Model Enterprise for Technological Innovation and a “National Enterprise Technology Center” recognized by five government ministries, Shisi Pharmaceutical has, in recent years, leveraged its core strengths to accelerate the coordinated advancement of generic drug development, innovative drug R&D, active pharmaceutical ingredient (API) production, and bioequivalence studies for generics. This strategic focus has steadily expanded the company’s product pipeline, continuously creating favorable opportunities and room for a transformative upgrade of Shisi Pharmaceutical’s product portfolio.

Keywords:

Shijiazhuang Sihua Pharmaceutical Ranked Among the Top 100 Enterprises in Shijiazhuang, Coming in at No. 16

Guangxiang Pharmaceutical of Shisiyao Group Approved to Establish a Postdoctoral Research Station

Shijiazhuang Sihua Pharmaceutical Ranked Among the Top 100 Enterprises in Shijiazhuang, Coming in at No. 16

Guangxiang Pharmaceutical of Shisiyao Group Approved to Establish a Postdoctoral Research Station